Obimet GX Forte 4mg Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 4mg and Metformin 1000mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. This dual-action mechanism addresses both insulin deficiency and insulin resistance, making Obimet GX Forte effective in managing hyperglycemia when diet and exercise alone are insufficient. The sustained-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Obimet GX Forte should be used under medical supervision, with regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, and gastrointestinal disturbances. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Dose adjustments may be necessary based on therapeutic response and tolerability. This combination therapy is a valuable option in the comprehensive management of type 2 diabetes to achieve and maintain target glycemic levels and reduce the risk of diabetes-related complications.